Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor update to the page template. This does not appear to modify any study details or eligibility information.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision: v3.6.4 is now displayed on the page, replacing v3.6.3. This indicates a minor update to the page template or underlying content management system.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision: v3.6.3 is now displayed on the page, replacing the previous v3.6.2. This reflects a minor update to the page’s revision tag without changes to the study content.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the page used for maintenance. This update does not modify visible content.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page loses several regulatory and documentation labels, including FDA-regulated status and IPD-related terms, along with associated descriptors, which changes how regulatory context and study documents are surfaced.SummaryDifference19%

- Check68 days agoChange DetectedNew helper sections were added to the study page (How to Read a Study Record, Common Questions, How to Join a Study); the Intervention/Treatment header was reformatted from 'Intervention / Treatment' to 'Intervention/Treatment', and the page footer revision label updated to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.